





PUBLICATIONS

Sr. No	Published	Title	Journal
1.	Phase 2 Human Clinical Trial https://doi.org/10.1016/S1473-3099(20)30942-7	Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report	THE LANCET Infectious Diseases
2.	Phase 1 Human Clinical Trial https://doi.org/10.1016/S1473-3099(21)00070-0	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.	THE LANCET Infectious Diseases
3.	Neutralization of UK Variant https://doi.org/10.1093/jtm/taab051	Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2	 JOURNAL of TRAVEL MEDICINE
4.	Hamster Efficacy Study https://doi.org/10.1016/j.isci.2021.102054	Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model.	 CellPress
5.	Non-Human Primate Efficacy Study https://doi.org/10.1038/s41467-021-21639-w	Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques	 nature COMMUNICATIONS
6.	Preclinical Safety and Immunogenicity https://doi.org/10.1016/j.isci.2021.102298	Th1 Skewed immune response of Whole Virion Inactivated SARS-CoV-2 Vaccine and its safety evaluation	 CellPress